Endocrine therapies such as aromatase inhibitors (AIs, Fig. 2A) are treatment options for postmenopausal women with ER + breast cancer and for premenopausal women with ER + breast cancers when combined with oophorectomy or ovarian suppression5. The gene discussed is ESR1; the disease is breast cancer.